Biovica records IVD test sales in Q3 of SEK 0.74m (460% above Q3 last year) and total sales of SEK 2...
Synthetic MR:s nettoomsättning i Q4-24 minskade med 58% till 12,6 MSEK, främst på grund av en långsa...
New targets: 8% org. growth, 12% EBITA margin, 15% ROCE Growth and margin targets imply 15%/12% upsi...
Redeye comments on Neola Medical’s directed issue, raising approximately SEK20m.
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 12 mars 2025 att Koncernen har ingå...
Redeye comments on yesterday’s press release from Dala Energi, stating that it intends to become a m...
Redeye initiates coverage of RaySearch, a software company offering treatment planning systems for r...
I februari 2025 bad EFSA (Europeiska myndigheten för livsmedelssäkerhet) om ytterligare tid för slut...
Messy quarter, but 2025 guidance firm & in line with ABGSCe Minor estimate changes, EBITA -1-2% on '...
With production now commenced at the 110MW Waste to Energy (WtE) plant in Finland, generating its fi...
EcoRub (”EcoRub” eller ”Bolaget”) levererar unika material där affärsidén är att förädla återvunnen ...
Soltech Energy navigerar en utmanande marknad men ser samtidigt starka framtidsmöjligheter.
Efter ett transformativt år 2024 går Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncer...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 10 mars 2025 att Bolaget har förlängt samar...
Redeye returns with an update following Alzecure's Q4 report.
Very weak SDR guidance triggers hefty estimate cuts Three key investor concerns unlikely to ease in ...
A leading education provider growing faster than peers Solid visibility—90% of academic year revenue...
Redeye leaves a short comment on WntResearch’s extraordinary general meeting.
Safello has announced it intends to launch of exchange-traded products (ETPs), a pivotal step to div...
Redeye comments on the Q4 report recently published by Cinclus Pharma’s peer, Phathom Pharmaceutical...
